Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spirit Airlines Inc SAVE

Spirit Airlines, Inc. offers affordable travel to value-conscious guests (Guests). The Company’s all-Airbus fleet is one of the most fuel efficient in the United States. It serves approximately 93 destinations in 15 countries throughout the United States, Latin America and the Caribbean. Its ultra low-cost carrier (ULCC) business model allows it to compete principally by offering Guests unbundled base fares that remove components traditionally included in the price of an airline ticket. It provides customizable travel options starting with an unbundled fare. This allows its Guests to pay only for the options they choose like bags, seat assignments, refreshments and Wi-Fi - something the Company call A La Smarte. The Company operate the Spirit Saver$ Club, which is a subscription-based loyalty program that allows members access to unpublished, extra-low fares as well as discounted prices on bags and seats, shortcut boarding and security. It also operates the Free Spirit loyalty program.


NYSE:SAVE - Post by User

Post by RomaJoyon Feb 05, 2022 2:09am
144 Views
Post# 34400477

FSD Pharma Inc: Lucid MS Video

FSD Pharma Inc: Lucid MS VideoFSD Pharma is pleased to share pre-clinical data demonstrating the effectiveness of its lead drug candidate, Lucid-MS, in treating Multiple Sclerosis. The unique potential therapeutic value of Lucid-MS is an industry-first and we want to share the visual evidence of functional recovery of pre-clinical subjects in this video!
<< Previous
Bullboard Posts
Next >>